Received Mar 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 4 | U7969AA | IM / LL |
| FLUN4 | INFLUENZA (SEASONAL) (FLUMIST QUADRIVALENT) | MEDIMMUNE VACCINES, INC. | 1 | WF2584 | IN / NS |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | TF27T | IM / RL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y013583 | SC / LL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y013583 | OT / LL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
No adverse effects reported; Improper storage of proquad; This spontaneous report was received from a Registered Nurse and refers to a(n) 3-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant medications included dtap ipv hep b hib vaccine Injection (manufacturer unknown) Havrix (Hepatitis a vaccine inact), Flumist (Influenza vaccine live reassort 3v) . On 20-Nov-2024, the patient started therapy with an improperly stored dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (lot #Y013583), dose number 1, administered by Subcutaneous route in Left Thigh (expiration date was not reported) for prophylaxis (improper storage of product in use). No adverse effects reported.; Sender's Comments: Priority : 5 , Is case serious : No , Index user : , Index date : 2025-02-26 , MNSC number : , CLIC number : , ESTAR number : , IRMS number : 03/08/2021 , Central date : 2025-02-20 , Classification : DMC, Attachment description : Post Marketing Basic , Safety case number :
Havrix; FluMist; Vaxelis